8. (#4, continued): AML patients: 1. Cytogenetics and molecular features consistent with adverse risk group. 2. Presence of minimal residual disease by multi-color flow cytometry or cytogenetics or molecular studies at the time of HSCT. 3. Presence of active disease defined as bone marrow blast count >5% but less than </=10% at the time of HSCT. 4. Peripheral blood blast count </=5% at HSCT.